Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $443.53 | 24 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $144.54 | 6 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $98.30 | 4 | $0 (2024) |
| Novo Nordisk Inc | $39.89 | 3 | $0 (2022) |
| Lilly USA, LLC | $36.08 | 2 | $0 (2024) |
| AbbVie Inc. | $33.77 | 2 | $0 (2023) |
| Abbott Laboratories | $28.40 | 2 | $0 (2024) |
| Amgen Inc. | $13.80 | 1 | $0 (2022) |
| GlaxoSmithKline, LLC. | $12.95 | 1 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $12.31 | 1 | $0 (2017) |
| Synergy Pharmaceuticals Inc | $11.84 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59.09 | 4 | Novartis Pharmaceuticals Corporation ($27.68) |
| 2023 | $30.08 | 2 | AbbVie Inc. ($16.51) |
| 2022 | $40.86 | 3 | Novo Nordisk Inc ($14.11) |
| 2021 | $17.26 | 1 | AbbVie Inc. ($17.26) |
| 2020 | $65.21 | 2 | AstraZeneca Pharmaceuticals LP ($45.71) |
| 2019 | $13.41 | 1 | Novo Nordisk Inc ($13.41) |
| 2018 | $151.65 | 6 | Novartis Pharmaceuticals Corporation ($70.62) |
| 2017 | $65.97 | 5 | AstraZeneca Pharmaceuticals LP ($41.29) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Diabetes Care | ||||||
| 09/05/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/09/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Diabetes | ||||||
| 09/01/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Diabetes Care | ||||||
| 07/27/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: NEUROSCIENCE | ||||||
| 08/22/2022 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: Inflammation | ||||||
| 07/26/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: Diabetes | ||||||
| 05/18/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $12.95 | General |
| Category: RESPIRATORY | ||||||
| 07/27/2021 | AbbVie Inc. | CREON (Drug) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/18/2020 | Lilly USA, LLC | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: Diabetes | ||||||
| 03/05/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $45.71 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/20/2019 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: Diabetes | ||||||
| 10/01/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $45.75 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/09/2018 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/27/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $11.79 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/26/2018 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/26/2018 | Synergy Pharmaceuticals Inc | Trulance (Drug) | Food and Beverage | In-kind items and services | $11.84 | General |
| Category: Gastroenterology | ||||||
| 02/06/2018 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $53.82 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/10/2017 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug), XARELTO | Food and Beverage | In-kind items and services | $12.31 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/19/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.08 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/07/2017 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/31/2017 | Novo Nordisk Inc | Victoza (Drug), Tresiba | Food and Beverage | In-kind items and services | $12.37 | General |
| Category: Diabetes | ||||||
| 01/30/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $11.96 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,664 | 3,952 | $374,003 | $215,144 |
| 2022 | 17 | 1,599 | 3,992 | $373,315 | $213,824 |
| 2021 | 24 | 1,931 | 5,227 | $790,499 | $282,862 |
| 2020 | 16 | 1,513 | 3,902 | $539,989 | $192,119 |
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 360 | 1,229 | $113,068 | $66,133 | 58.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 191 | 927 | $87,138 | $53,558 | 61.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 177 | 206 | $52,530 | $25,392 | 48.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 197 | 329 | $44,744 | $24,031 | 53.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 169 | 183 | $25,071 | $15,229 | 60.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 100 | 100 | $14,000 | $11,671 | 83.4% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2023 | 104 | 137 | $7,124 | $6,888 | 96.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 170 | 491 | $11,712 | $3,928 | 33.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 34 | 37 | $3,441 | $2,182 | 63.4% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 39 | 86 | $2,150 | $1,395 | 64.9% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 19 | 19 | $3,230 | $1,270 | 39.3% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 22 | 24 | $2,208 | $1,142 | 51.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 23 | 30 | $3,660 | $1,116 | 30.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 13 | 16 | $896.00 | $603.45 | 67.3% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 18 | 107 | $1,605 | $379.63 | 23.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 28 | 31 | $1,426 | $224.62 | 15.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 373 | 1,284 | $118,128 | $66,893 | 56.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 166 | 939 | $88,266 | $48,986 | 55.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 194 | 358 | $48,688 | $29,505 | 60.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 163 | 198 | $50,490 | $28,378 | 56.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 147 | 172 | $23,564 | $12,990 | 55.1% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2022 | 130 | 179 | $9,306 | $9,081 | 97.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 73 | 73 | $9,941 | $8,551 | 86.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 117 | 328 | $7,872 | $3,064 | 38.9% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 52 | 118 | $2,950 | $1,923 | 65.2% |
About Dr. Greg Smart, M.D
Dr. Greg Smart, M.D is a Family Medicine healthcare provider based in El Dorado, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073506010.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Greg Smart, M.D has received a total of $443.53 in payments from pharmaceutical and medical device companies, with $59.09 received in 2024. These payments were reported across 24 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($443.53).
As a Medicare-enrolled provider, Smart has provided services to 6,707 Medicare beneficiaries, totaling 17,073 services with total Medicare billing of $903,947. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Other Specialties Emergency Medicine, Hospitalist
- Location El Dorado, AR
- Active Since 08/24/2005
- Last Updated 06/14/2010
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1073506010
Products in Payments
- ENTRESTO (Drug) $98.30
- FARXIGA (Drug) $81.58
- LOKELMA (Drug) $45.71
- FREESTYLE LIBRE 3 (Device) $28.40
- TRULICITY (Drug) $19.50
- CREON (Drug) $17.26
- BRILINTA (Drug) $17.25
- MOUNJARO (Drug) $16.58
- VRAYLAR (Drug) $16.51
- Rybelsus (Drug) $14.11
- Otezla (Drug) $13.80
- Ozempic (Drug) $13.41
- TRELEGY ELLIPTA (Drug) $12.95
- Victoza (Drug) $12.37
- INVOKANA (Drug) $12.31
- Trulance (Drug) $11.84
- LINZESS (Drug) $11.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in El Dorado
Crystal Faudere, D.o, D.O
Family Medicine — Payments: $15,929
Diane Nightengale, M.d, M.D
Family Medicine — Payments: $13,382
Mr. Robert Watson, Md, MD
Family Medicine — Payments: $4,443
Dr. Matthew Callaway, Md, MD
Family Medicine — Payments: $4,432
Dr. Deanna Hopson, M.d, M.D
Family Medicine — Payments: $3,382
Dr. Christina Cooper, M.d, M.D
Family Medicine — Payments: $3,378